[{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Not Applicable"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid Based SPX-069","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by SpectrumX

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SPX-001 is SpectrumX’s nebulised respiratory infection drug candidate, based on the Company’s licensed hypochlorous acid (HOCl)-based SPC-069 drug substance, which is believed to have broad-spectrum antipathogenic properties.

                          Brand Name : SPX-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 24, 2022

                          Lead Product(s) : Hypochlorous Acid Based SPX-069

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001.

                          Brand Name : SPX-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 20, 2022

                          Lead Product(s) : SPX-001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SpectrumX has confirmed scientific advice meeting with MHRA and will discuss the available data supporting the commencement of human trials with SPX-001 (Hypochlorous Acid) protocol for Phase Ib human volunteer study, prior to submission of CTA submissio...

                          Brand Name : SPX-001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 08, 2022

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.

                          Brand Name : SPX-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 03, 2022

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank